이식형 심장 박동 관리 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Implantable Cardiac Rhythm Management Devices Market Growth & Trends:

The global implantable cardiac rhythm management devices market size is expected to reach USD 15.53 billion by 2030, registering to grow at a CAGR of 6.4% from 2024 to 2030 according to a new report by Grand View Research, The increasing global geriatric population prone to CVD diseases and the demand for accurate and effective diagnostics of these diseases are the factors contributing to the growth of implantable cardiac rhythm management (CRM) devices.

Cardiac disorders are one of the major causes of mortality around the world, with a large percentage of the population suffering from some form of cardiac disorder in their lifetime. While the older population is at a higher risk, the prevalence of CVDs is increasing in the younger generation as well. Hectic schedules and busy lifestyles are major factors for hypertension among individuals. Various implantable devices are being used for improved cardiac performance, including pacemakers, ICDs, and Cardiac Resynchronization Therapy (CRT) devices. Pacemakers are the most implanted devices for conduction disorders and sinus dysfunctions. CRT devices and ICDs are comparatively new and incorporate better technology than their older counterparts.

The COVID-19 pandemic adversely impacted the market, in particular the ICDs market, with dampened demand and sales during 2020. The sales improved as the hospitals resumed elective surgeries. However, the progression of COVID-19 in several key markets continued to create uncertainty during the year. Abbott, for instance, reported improvement in its hospital-based businesses during Q2 and Q3 2020. However, the improving trends flattened or were negatively impacted during Q4 2020 due to a sudden increase in COVID-19 cases and hospitalizations in many countries. Nihon Kohden, on the other hand, reported strong sales growth of defibrillators in 2020, despite inhibited sales activity due to the pandemic.

Cardiac disorders are one of the major causes of mortality around the world, with a large percentage of the population suffering from some form of cardiac disorder in their lifetime. While the older population is at a higher risk, the prevalence of CVDs is increasing in the younger generation as well. Various implantable devices are being used for improved cardiac performance, including pacemakers, ICDs, and Cardiac Resynchronization Therapy (CRT) devices. Implanted pacemakers are majorly used for conduction disorders and sinus dysfunctions.

Implantable Cardiac Rhythm Management Devices Market Report Highlights:

• The hospital's end-use segment captured the largest revenue share of over 68.9% in 2023. The growth can be attributed to deeper product penetration, a large volume of surgical procedures, and rising patient footfall
• The ICDs product segment held the largest revenue share in 2023. The cardiac resynchronization therapy devices segment is expected to register the fastest growth rate over the forecast period
• An estimated 85.7 million Americans (i.e., almost 34% of the population) suffered from high blood pressure and hypertension due to stressful lifestyles. Almost 23.4 million American adults were diagnosed with diabetes in 2017, while an estimated additional 7.6 million American adults are undiagnosed diabetics. Globally, the prevalence of diabetes is expected to increase to 7.7% in 2030
• The CRT product segment is anticipated to register the fastest growth rate over the forecast period due to the implementation of supportive legislative policies in developed countries and an increase in awareness and the number of training programs for use of the products
• North America dominated the market with a revenue share of over 47.6% in 2023. This can be attributed to an increase in the incidence of cardiovascular diseases, supportive government policies, favorable reimbursement schemes, a rise in awareness, and an increase in the number of training programs
• Asia Pacific is expected to exhibit the fastest CAGR during the forecast period due to the higher prevalence of CVDs and rapidly aging population

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Segment
  • 2.2.2. End-use Segment
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Implantable Cardiac Rhythm Management Device Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of arrhythmia disorders
    • 3.2.1.2. Technological advancements in device functionality
    • 3.2.1.3. Rising Heart failure (HF) cases
    • 3.2.1.4. Growing geriatric population
    • 3.2.1.5. Favorable reimbursement policies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent Regulatory Policies
• 3.3. Implantable Cardiac Rhythm Management Device Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Implantable Cardiac Rhythm Management Device Market: Product Estimates & Trend Analysis

• 4.1. Implantable Cardiac Rhythm Management Device Market: Product Dashboard
• 4.2. Implantable Cardiac Rhythm Management Device Market: Product Movement Analysis
• 4.3. Implantable Cardiac Rhythm Management Device Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Pacemaker
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.2. Conventional Pacemakers
    • 4.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.3. Leadless Pacemaker
    • 4.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. ICDs
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Single Chamber ICDs
    • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Dual Chamber ICDs
    • 4.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. CRT
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6.2. CRT-Defibrillator
    • 4.6.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6.3. CRT-Pacemaker
    • 4.6.3.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Implantable Cardiac Rhythm Management Device Market: End-use Estimates & Trend Analysis

• 5.1. Implantable Cardiac Rhythm Management Device Market: End-use Dashboard
• 5.2. Implantable Cardiac Rhythm Management Device Market: End-use Movement Analysis
• 5.3. Implantable Cardiac Rhythm Management Device Market Size & Forecasts and Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Specialty Cardiac Centers
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Implantable Cardiac Rhythm Management Device Market: Regional Estimates & Trend Analysis by Country, Product, End-use, & End-use

• 6.1. Global Implantable Cardiac Rhythm Management Device Market: Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 6.3. North America
  • 6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Regulatory framework/ reimbursement structure
    • 6.3.4.3. Competitive scenario
    • 6.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.9. Denmark
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Regulatory framework/ reimbursement structure
    • 6.4.9.3. Competitive scenario
    • 6.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.3. South Africa
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Medtronic
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. End-use benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Abbott
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. End-use benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Boston Scientific Corporation
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. End-use benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Koninklijke Philips N.V.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. End-use benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Zoll Medical Corporation
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. End-use benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Biotronik
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. End-use benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Stryker
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. End-use benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Schiller AG
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. End-use benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Nihon Kohden Corporation
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. End-use benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Microport Scientific Corporation
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. End-use benchmarking
    • 7.3.13.4. Strategic initiatives